Active Not RecruitingNCT07217860
Long-term azetukalner for depression in people with bipolarity type I or II
About this title
Read the official source — NCT07217860Researchers are studying Azetukalner, tracking side effects to assess long-term safety and tolerability in people with bipolarity type I or II during a depressive episode.
Medication studyAges 18–75United States
Understand this study
What is this study about?
Researchers are studying Azetukalner, tracking side effects to assess long-term safety and tolerability in people with bipolarity type I or II during a depressive episode.
Who could participate?
This study is for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
- Listed locations
- Little Rock and 19 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 30, 2025
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 400
- Sponsor
- Xenon Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT07217860
- Official title
Show the full official title
A Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bipolar I or II Depression
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock · Rogers · Bellflower
16 more locations
- Culver City
- Riverside
- Coral Gables
- Jacksonville
- Miami
- Orlando
- Atlanta
- Decatur
- Stone Mountain
- Orland Park
- Cherry Hill
- Cedarhurst
- Allentown
- Memphis
- Wichita Falls
- Everett
About the molecule
When a study medicine is clearly identified, HopeStage adds a short explanation of what that molecule is and links back to reliable public sources.
Azetukalner
an experimental Kv7 potassium-channel opener
targets Kv7 potassium channels
Questions about this study
What is this study about?
Researchers are studying Azetukalner, tracking side effects to assess long-term safety and tolerability in people with bipolarity type I or II during a depressive episode.
Who is behind this study?
The study sponsor is Xenon Pharmaceuticals Inc.
Does this study involve medication?
Yes. The study involves medication, including Azetukalner.
Who can participate?
This study is for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
